JUL 2 4 2006 8

Complete if Known

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1

	Complete II Known				
	Application Number	10/565,484	_		
	Filing Date	01/17/2006			
	First Named Inventor	Nai-Kong V. Cheung			
	Art Unit	1623	_		
	Examiner Name	Not Yet Known	_		
Ī	Attorney Docket Number	639-C-PCT-US	_		

PTO/SB/08A (04-03)

Examiner Initials*	Cite No.1	No.1 MM-DI	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
/ESO/	1	US- 3,987,166	10-19-1976	Komatsu et al.	Figures Appear
/ESO/	2	US- 5,622,939	04-22-1997	Jamas et al.	· · · · · · · · · · · · · · · · · · ·
/ESO/	3	us- 5,980,918	11-09-1999	Barbara K. Klein	
/ESO/	4	^{US-} 5,189,028	02-23-1993	Nikl et al.	
/ESO/	5	US- 4,833,131	05-23-1989	Williams et al.	
/ESO/	6	US- 5,130,127	07-14-1992	Dorothy Herlyn	
/ESO/	7	us- 4,761,402	08-02-1988	Williams et al.	
/ESO/	8	us- 4,818,752	04-04-1989	Williams et al.	
/ESO/	9	us- 5,849,720	12-15-1998	Jamas et al.	
/ESO/	10	US- 6,573,245	06-03-2003	Dante J. Marciani	
/ESO/	11	us- 6,143,883	11-07-2000	Lehmann et al.	
/ESO/	12	^{US-} 6,664,370	12-06-2003	Martin A. Cheever	
/ESO/	13	us- 7,070,778	07-04-2006	Yvin, et al.	
		US-			

FOREIGN PATENT DOCUMENTS							
olumns, Lines, slevant Passages							
ant Figures Appear							

Examiner Signature	/Eric Olson/	Date Considered	02/13/2008

"EXAMINET. Initial if deterring consistency, whether or not classion is in conformance with MPEP 698. Draw time through classion is not in conformance and not considered. Schools copy of the form with next communication is applicant." Applicant's undeer classion designation number (optional): "See Kinds Codes of USPTO Peter Documents as investigation or MPEP 99 10 A. Experience and the conformation of the second or control or control of the second or control of the second or control of the second or control or c

The endurant enturnations in required by 37 CRR 197 and 198. The information is required to option or retain a burnel by the public which is to list part by the USEPTO as processing in application. Confidentially is governed by 38 U.S.C. 128 and 37 CRR 11.4 This collection is estimated to take 3 hours complete. Publication of the USEPTO as processing and submitting the completed application from the USEPTO in this collection is estimated to take 3 hours complete, including gathering, preparing, and submitting the completed application from the USEPTO. This will vary depending over the effective of the USEPTO. This will vary depending over the effective of the USEPTO. This will vary depending over the effective of the USEPTO. The USEPTO is the end of the USEPTO. The USEPTO is the USEPTO IS THE USEPTO IS THE USEPTO IN THE USEPTO IS THE USEPTO IS THE USEPTO IS THE USEPTO IN THE USEPTO IS THE USEPTO IS THE USEPTO IS THE USEPTO IN THE USEPTO IS THE USEP

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Petent end Trademic Office; U.S. DEPARTMENT OF COMMERCE
Under the Peperwork Reduction Act of 1995, no persons are required to respond to e collection of Informetion unless it contains a velid OMB control number.

INFOR STATE	te for form 1449/PTO			Complete if Known			
				Application Number	10/565,484		
INF	ORMATION	DIS	CLOSURE	Filing Date	01/17/2006		
STA	TEMENT B	BY A	PPLICANT	First Named Inventor	Nai-Kong V. Cheung		
	(Use as many she	nte se e		Art Unit	1623		
	(Ose as many sne	ota ea n	ocessary)	Examiner Name	Not Yet Known		
Sheet	2	of	8	Attorney Docket Number	639-C-PCT-US		
			•		·		

		OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
/ESO/	14	U.S. Patent Application Publication No. US 2004/0248772 A1 for Akikuni Yagita, December 9, 2004 for 'Anlicancer Compositions'	
/ESO/	15	U.S. Patent Application Publication No. US 2004/0266726 A1 for Akkuni Yagita, December 30, 2004. "Anticancer Compositions"	
/ESO/	16	U.S. Patent Application Publication No. US 2003/0180254 A1 for Lane et al., September 25, 2003, for 'Immunologic Enhancement with Intermittent Interleukin-2 Therapy'	
/ESO/	17	U.S. Patent Application Publication No. US 2004/0109857 A1 for Chu et al., June 10, 2004, for "Methods of Therapy for B-cell Malignancies using Antagonist Anti-CD40 Antibodies"	
/ESO/	18	European Patent Publication No. EP 0194851 A2 for The Wistar Institute et al., September 17, 1986 for "Human tumor therapy".	
/ESO/	19	Japanese Patent Publication No. JP 62252730 A2 for Takeda Chem. Ind. Ltd. et al., November 4, 1987 for 'Antitumor Agent'	
/ESO/	20	Japanese Patent Publication No. JP 63307825 A2 for Nippo Beet Sugar MFG Co. Ltd. et al., December 15, 1988 for 'Anlitumor Agent and Production Thereof'.	
/ESO/	21	International Patent Publication No. WO 2004/014320 A2 for Biopolymer engineering, Inc. et al., February 19, 2004 for "Methods of using beta glucan as a radioprotective agent".	
/ESO/	22	International Patent Publication No. WO 2004/14320 A3 for Biopolymer engineering, Inc. et al., February 19, 2004 for Methods of using beta glucan as a radioprotective*, Published with September 2, 2004 International Search Report.	
/ESO/	23	International Patent Publication No. WO 2004/021994 A2 for Biopolymer engineering, Inc. et al., March 18, 2004 for "Cancer therapy using whole glucan paticles and antibodies".	

Examiner Signature	/Eric Olson/	Date Considered	02/13/2008

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Considered. Include copy of the following the Communication of population brakes a check mash have I English Ising-ago Translation is etissated.

This collection of Inministration is equirated by 37 CFR 198. The information is required to obtain or relate to bearful by the Duble to the loss of the bearful by the Duble to the loss of the bearful by the Duble to process) on application. Confidentially is governed by 35 U.S. C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to be fine or proper properties of the process of the properties of the

Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PT			e required to respond to e collection of information unless it contains e valid OMB control number. Complete if Known		
			Application Number	10/565,484	
INFORMATIO			Filing Date	01/17/2006	
STATEMENT	BY A	PPLICANT	First Named Inventor	Nai-Kong V. Cheung	
(Use as many	sheets as n	ecossarvi	Art Unit	1623	
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		,	Examiner Name	Not Yet Known	
Sheet 3	of	8	Attorney Docket Number	639-C-PCT-US	

		OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/ESO/	24	International Patent Publication No. WO 2004/21994 A3 for Biopolymer engineering, Inc. et al., March 18, 2004 for "Carner therapy using whole glucan particles and antibodies", Published with August 12, 2004 International Search Report.	
/ESO/	25	International Patent Publication No. WO 00/15/238 for NABI et al., March 23, 2000 for "Composition of 8-glucans and specific IGIV", Published with August 31, 2000 International Search Report.	
/ESO/	26	International Patent Publication No. WO 01/62283 A2 for BIOTECH ASA et al., August 30, 2001 for "Novel, Non-arriigenic, Muscosal Adjuvant Formulation which modulates the effects of substances, including vaccine antigens, in contact with mucosal body surfaces".	
ESO/	27	International Patent Application Publication No. WO 98/39013 for Peregrine Pharmaceutical, Inc. et al., September 11, 1998 for "Composition and Method for Treating Cancer and Immunological Disorders Resulting in Chronic Conditions".	
/ESO/	28	PCT International Preliminary Examination Report for Stoan-Kettering Institute for Cancer Research, int'l Application No. PCT/US02/01276, Filed January 15, 2002, Dated March 27, 2003.	
/ESO/	29	PCT International Search Report for Sloan-Kettering Institute for Cancer Research, Int'l Application No. PCT/US04/23099, Filed July 16, 2004, Dated February 28, 2005.	
/ESO/	30	PCT International Search Report for Sloan-Kettering Institute for Cancer Research, Int'l Application No. PCT/USG4/23099, Filed July 16, 2004, Dated April 14, 2005.	
/ESO/	31	PCT Written Opinion of the International Searching Authority for Sloan-Kettering Institute for Cancer Research, Int'l Application No. PCT/US04/23099, Filed July 16, 2004, Dated April 14, 2005.	
/ESO/	32	PCT International Search Report for Stoan-Kettering Institute for Cancer Research, Int'l Application No. PCT/IUS02/01276, Filed January 15, 2002, Dated June 5, 2002.	
/ESO/	33	PCT Written Opinion for Sloan-Kettering Institute for Cancer Research, et al, Int1 Application No. PCT/USO2/01276, Filed January 15, 2002, Dated November 25, 2002.	

Examiner	/Eric Olson/	Date	02/13/2008
Signature	7.8810 0.0071	Considered	02/10/2000

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

EXAMINET: Initial if reference considered, whether or not classion is in conformance with MEPE 609. Draw line through classion if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique classion designation number (postcoral). 2 Applicant is to place a chock mark here it English lenguage Translation is attached.

1 Applicant's unique classion designation number (postcoral). 2 Applicant is to place a chock mark here it English lenguage Translation is attached. In the control of the contro

Approved for use through 04/30/2003. OMB 0651-0031

639-C-PCT-US

Under the Paperwork Reduction Act of 1995, no persons an		nt and Trademerk Office; U.S. DEPARTMENT OF COMMER on of information unless it contains a valid OMB control numb	
Substitute for form 1449/PTO		Complete if Known	1
	Application Number	10/565,484	
NFORMATION DISCLOSURE	Filing Date	01/17/2006	
STATEMENT BY APPLICANT	First Named Inventor	Nai-Kong V. Cheung	_
(Use as many sheets as necessary)	Art Unit	1623	
(Ose as many sneets as necessary)	Examiner Name	Not Yet Known	_

Attorney Docket Number

		OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, calalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/ESO/	34	PCT International Preliminary Report on Patentability for Sloan-Kettering Institute for Cancer Research, et al., Int'l Application No. PCT/US2004/023099, Filed July 16, 2004, Dated January 26, 2006.	
/ESO/	35	PCT Corrected Written Opinion of the International Searching Authority for Sloan-Kettering Institute for Cancer Research, et al, Int'l Application No. PCT/US04/23099, Filed July 16, 2004, Dated August 10, 2005.	
/ESO/	36	PCT Corrected International Search Report for Sloan-Kettering Institute for Cancer Research, et al. Int'l Application No. PCT/US2004/23099, Filed July 16, 2004, Dated August 10, 2005	
/ESO/	37	Search Report prepared by the Norwegian Patent Office, dated May 4, 2005	
/ESO/	38	Allendorf et al., "Macrophages shuttle orally administered 6-glucan to potentiate the CR3-dependent tumoricidal effects of monoclonal antibodies in mouse tumor models", FASEB Journal, Vol. 17, No. 7, Page C128 (2004).	
/ESO/	39	Arturson, G. et al., "Intravascular Persistence and Renal Clearance of Dextran of Different Molecular Sizes in Normal Children", Arch. Dis. Childh., Vol. 41, Pages 168-172 (1966).	
/ESO/	40	Arturson, G.; Wallenkus, G., "The Renal Clearance of Dextran of Different Molecular Sizes in Normal Humans", Scandinaz J. Clin & Lab Investigation, Vol. 1, Pages 81-86 (1964).	
/ESO/	41	Babineau, T. et al., "A Phase II Multicenter, Double-blind, Randomized, Placebo-Controlled Study of Three Dosages of an Immunomodulator (PGG-Glucan) in High-Risk Surgical Patients", Arch. Surg., Vol. 129, Pages 1204-121	
/ESO/	42	Babineau, T. et al., 'Randomized Phase I/II Trial of a Macrophage-Specific Immunomodulator(PGG-Glucan) in High-Risk Surgical Patients', Annals of Surgery, Vol. 220, No. 5, Pages 601-609(1994).	
/ESO/	43	Basic and Clinical Pharmacology, 7th edition 1998, Bertram G. Katzung, pp. 881-884	

Examiner /Fric Olson/ Date 02/13/2008				
Signature	Signature	/Eric Olson/	Date Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet

4

18

Application include output or comparison number (foreigned). 2 particularly of the process of th

Approved for use through 04/30/2003. OMB 0651-0031
U.S. Petent and Trademerk Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to e collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449/PTO Application Number 10/565.484 INFORMATION DISCLOSURE Filing Date 01/17/2006 STATEMENT BY APPLICANT First Named Inventor Nai-Kong V. Cheung Art Unit (Use as many sheets as necessary) Examiner Name Not Yet Known Attorney Docket Number Sheet 5 18 of 639-C-PCT-US

		OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T²
/ESO/	44	Cheung, N.: Modak, S., "Oral (1-3),(1-4)-8-D-Glucan Synergizes with Anliganglioside GD2 Monoclonal Anlibody SF8 in the Therapy of Neuroblasioma", Clinical Cancer Research, Vol. 8, Pages 1217-1223 (2002).	
/ESO/	45	Cheung, N.K. et al., "Orally administered 8-glucans enhance anti-tumor effects of monocional antibodies", Cancer Immunol Immunother. 2002 Nov; 51(10):557-564.	
/ESO/	46	Chihara, G. et al., "Antitumor and Metastasis-Inhibitory Activities of Lentinan as an Immunomodulator: An Overview", Cancer Detection and Prevention Supplement Vol. 1, Pages 423-443(1987).	
/ESO/	47	Delinger, E., et al., "Effect of PGG-glucan on the Rate of Serious Postoperative Infection or Death Observed After High Risk Gastrointestinal Operations", Arch. Surg., Vol 134, Pages 977-983 (1999).	
/ESO/	48	Hansue, H. et al., "Basic Studies on Oral Administration of Lentinan (I)*, J. Jpn. Soc. Cancer Ther., Vol. 8, Pages 1566-1571(1989).	
/ESO/	49	Hanaue, H., Y. Tokuda, T. Machimura, A. Kamijoh, Y. Kondo, K. Ogoshi, H. Makuuchi, H. Nakasaki, T. Tajima, and T. Milomi. 1989. "Effects of oral lentinan on T-cell Subsets in Peripheral Venous Blood". Clin. Ther. 11514-622.	
/ESO/	50	Hayakawa, K., N. Mitsuhashi, Y. Saito, M. Takahashi, S. Katano, K. Shiojima, M. Furuta, and H. Niibe. 1993. 'Effect of Krestin (PSK) as Adjuvant Treatment on the Prognosis after Radical Radiotherapy in Patients with Non-small Cell Lung Cancer. Anticancer Res. 1:1815-1820.	
/ESO/	51	Hong et al., Mechanism by Which Orally Administered 8-1,3-Glucans Enhance the Tumoricidal Activity of Antitumor Monoclonal Antibodies in Murine Tumor Models*, The Journal of Immunology, Vol. 173, No. 5, Pages 179-806 (2004).	
/ESO/	52	Hotta, H., K. Hagiwara, K. Tabata, W. Ito, and M. Homma. 1993. "Augmentation of protective immune responses against Sendai virus infection by fungal polysaccharide schizophyllan". Int. J. Immunopharmacol. 15:55-80	
/ESO/	53	Morinaga, H., K. Tazawa, H. Tagoh, A. Muraguchi, and M. Fujimaki. 1994. 'An in vivo study of hepatic and splenic interteukin-13 mRNA expression following oral PSK or LEM administration'. Gann 85:1298-1303	

Examiner	/Eric Olson/	Date	02/13/2008	1
Signature		Considered	02/13/2000	1

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

considered. Include copy of this form with next communication to applicant.

considered. Include copy or one some wan nex communication to appreciant.

Applicant's range clusted necessaries number optional, 2 Spiciant is to place o check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 138. The information is required to obtain or retain elsentifit by the public which is to file (and by the USPTO to process) any application. Confiderabilities (personal by 38 U.S. 7.12 and 37 CFR 114. This collection is estimated to bate 120 minutes to complete, including patheting, preparing, and submitting the completed application from to the USPTO. Time will very deponding upon this individual case. Any comments on the market of the process of the Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

Approved for use through 04/30/2003. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

639-C-PCT-US

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449/PTO Application Number 10/565,484 INFORMATION DISCLOSURE Filing Date 01/17/2006 STATEMENT BY APPLICANT First Named Inventor Nai-Kong V. Cheung Art Unit 1623 (Use as many sheets as necessary) Examiner Name Not Yet Known

Attorney Docket Number

	Lau	OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
/ESO/	54	Nanba, H. 1995. "Activity of Maitake D-faction to Inhibit Carcinogensis and Metastasis". Ann. N. Y. Acad. Sci. 768:243-245	
/ESO/	55	Nanba, H. and H. Kuroda. 1987. "Antitumor Mechanisms of Orally Administered Shitlake Fruit Bodies". Chem. Pharm. Bull. (Tokyo) 35:2459-2464	
/ESO/	56	Nanba, H. and H. Kuroda. 1988. "Potentiation of Host-Mediated Antitumor Activity by Orally Administered Mushroom (Agaricus bispora) Fruit Bodies". Chem. Pharm. Bull. (Tokyo) 36:1437-1444.	
/ESO/	57	Hishida, I., H. Nanba, and H. Kuroda. 1988. "Anlitumor Activity Exhibited by Orally Administered Extract from Fruit Body of Grifola frondosa (Mattake)". Chem. Pharm. Bull (Tokyo) 36:1819-1827	
ESO/	58	lino, Y., T. Yokoe, M. Maemura, J. Horiguchi, H. Takei, S. Ohwada, and Y. Morishita. 1995. 'Immunochemotherapies verus Chemotherapy as Adjuvant Treatment after Curative Resection of Operable Breast Cancer', Anticancer Res. 15:2907-2912.	
/ESO/	59	Kldd, P., 'The Use of Mushroom Glucans and Proteoglycans in Cancer Treatment', Alternative Medicine Review, Vol. 5, No. 1, Pages 4-27(2000).	
/ESO/	60	Mayer, L.; Shao, L., "Therapeutic Potential of Oral Tolerance", Nature Reviews Immunology, Vol. 4, Pages 407-419(2004).	
/ESO/	61	Mehvar, R., "Recent Trends in the Use of Polysaccharides for Improved Delivery of Therapeutic Agents: Pharmacokinetic and Pharmacodynamic Perspectives", Current Pharmaceutical Biotechnology, Vol. 4, Pages 283-302(2003)	
/ESO/	62	Nanba, H., K. Mori, T. Toyomasu, and H. Kuroda. 1987. 'Antitumor action of shitlake (Lentinus edodes) fruit bodies orally administered to mice'. Chem. Pharm. Bull. (Tokyo) 35:2453-2458	
/ESO/	63	Ohmori, T., K. Tamura, A. Wakaiki, G. Kawanishi, S. Tsuru, T. Yadomae and K. Nomoto. 1988. "Dissociation of a Glucan Fraction (CO-1) from Protein-bound Polysaccharide of Cordyceps ophioglossides and Analysis of its Antitumor Effect. Chem. Pharm. Bull. (Tokyo,) 364512-4518	

Examiner Signature	/Eric Olson/	Date Considered	02/13/2008

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Drew line through citation if not in conformance and not

18

of

Sheet 6

considered. Include copy of this form with next communication to applicant.

considered include copy of the storm with not dominimization to applications, the property of the control of th

Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

639-C-PCT-US

Under the Paperwork Reduction Act of 1995, no persons are required to respond to e collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449/PTO Application Number 10/565,484 INFORMATION DISCLOSURE **Filing Date** 01/17/2006 STATEMENT BY APPLICANT First Named Inventor Nai-Kong V. Cheung Art Unit 1623 (Use as many sheets as necessary) Examiner Name Not Yet Known

Attorney Docket Number

	OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS	
Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
64	Ostroff et al., "Immune-Enhancing Effects of Oral Yeast & 1,3/1,6 Glucans", American Chemical Society, Vol. 225, No.1-2, pp. AGFD 8 (2003).	
65	Papila et al., "The Effect of Oral 8-glucan in Addition to Systemic Chemotherapy on the Leukocyte Values and Oral Mucositis in the Patients with Head-neck Tumors", International Review of Allergology & Clinical Immunology, Vol 10, No.2, Pages 59-5(2004).	
66	Ross, et al., "Therapeutic intervention with complement and 6-glucan in cancer", Immunopharmacology 42(1999), 61-74.	
67	Sakurai, T., K. Hashimoto, I. Suzuki, N. Ohno, S. Oikawa, A. Masuda, and T. Yadomae. 1992. "Enhancement of Murine Alveolar Macrophage Functions by Orally Administered 6-glucan". Int. J. Immunopharmacol. 14:821-830.	
68	Shimazu, H. et al., "Intravenous chronic toxicity of lentinan in rats: 6-month treatment and 3-month recovery (author transl.)", National Library of Medicine (PubMed), J Toxicol Sci., Pages 33-57 (1985).	
69	Sortwell, R. et al., "Chronic Intravenous Administration of Lentinan to the Rhesus Monkey", Toxicology Letters, Vol. 9, Pages 81-85 (1981).	
70	Suzuki, et al., "Effect of orally administered 8-glucan on macrophage function in mice". Int. J. Immunopharmacology 12:6, 675-684, 1990.	
71	Suzuki, M. et al., "Antitumor and Immunological Activity of Lentinan in Comparison with LPS", International Society for Immunopharmacology, Pages 463-468(1994).	
72	Suzuki, I., K. Hashimoto, N. Ohno, H. Tanaka, and T. Yadomae. 1989. Immunomodulation by Orally Administered B-glucan in Mice.* Int. J. Immunopharmacol. 11:761-769.	
73	Suzuki, I., T. Sakurai, K. Hashimoto, S. Oikawa, A. Masuda, M. Ohsawa, and T. Yadomae. 1991. "Inhibition of Experimental Pulmonary Metastasis of Lewis Lung Carcinoma by Orally Administered &-glucan in Mice". Chem. Pharm. Sult. (Tokyo) 39:1006-1008	
	64 65 66 67 68 69 70 71	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. Ostroff et al., "Immune-Enhancing Effects of Oral Yeast 8 1,3/1,6 Glucans", American Chemical Society, Vol. 225, No.1-2, pp. AGPD 9 (2003). Papilla et al., "The Effect of Oral S-glucan in Addition to Systemic Chemotherapy on the Leukocyte Values and Oral Mucositis in the Patients with Head-neck Tumors, International Review of Allergology, & Clinical Immunology, Vol 10, No.2, Pages 59-8 (2004). Ross, et al., "Therapeutic intervention with complement and 6-glucan in cancer", Immunopharmacology 42(1999), 61-74. Ross, et al., "Therapeutic intervention with complement and 6-glucan in cancer", Immunopharmacology 42(1999), 61-74. Ross, et al., "Therapeutic intervention with complement and 6-glucan in cancer", Immunopharmacology 42(1999), 61-74. Ross, et al., "Thrapeutic intervention with complement and 6-glucan in cancer", Immunopharmacology 42(1999), 61-74. Ross, et al., "Thrapeutic interventions by Orally Administered 6-glucan" in J. Immunopharmacol. 14: 821-830. Shimzuk, J. et al., "Intravenous chronic toxicity of tentinan in rats: 6-month treatment and 3-month recovery (eithor transl.)", National Library of Medicine (PubMed), J Toxicol Sci., Pages 33-57 (1980). Sortivell, R. et al., "Chronic Intravenous Administration of Lentinan to the Rhesus Monkey", Toxicology Letters, Vol. 9, Pages 81-85 (1981). Suzuki, M. et al., "Affect of orally administered 6-glucan on macrophage function in mice". Int. J. Immunopharmacology, Pages 463-468 (1994). Suzuki, I., K. Hashimoto, N. Ohno, H. Tanaka, and T. Yadomae. 1989. "Immunomodulation by Orally Administered 6-glucan in Mice", Int. J. Immunopharmacology, Pages 463-468 (1994). Suzuki, I., K. Hashimoto, S. Okawa, A. Massuds, M. Ohsawa, and T. Yadomae. 1991. "Inhibition of Experimental Pulmo

		_	
Examiner	/Esta Olaza/	Date	00/40/0000
Signature	/Eric Olson/	Considered	02/13/2008

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

18 of

Sheet

considered. Include copy of this form with next communication to applicant.

consource. Include copy of this som with next communication to applicant.

Applicant's using classification degration in unbiner optionals, 2 Applicant is to place a check mark here if English language Transistion is attached.

This collection of information is required by 37 CFR 1.89 popular to the property of the property of the public which is to flee (gred by the USPTO. The top to process) are application. Conditionality is governed by 38 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 122 minutes to complete, including to process) are application. Conditionality is governed by 38 U.S.C. 122 and 127 CFR 1.14. This collection is estimated to take 122 minutes to complete, including quithering, preparing, and submitting the completed application from to the USPTO. Time will vary dropending upon the individual case. Any comments on the mount of time you be sent to the Chief Information Officer, U.S. Patert and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

Approved for use through 04/30/2003. OMB 0651-0031

Substitute for form 1449/PTO				e required to respond to e collection of information unless it conteins a velid OMB control number Complete if Known		
				Application Number	10/565,484	
INF	ORMATION	DISC	CLOSURE	Filing Date	01/17/2006	
STATEMENT BY APPLICANT			PLICANT	First Named Inventor	Nai-Kong V. Cheung	
	(Use as many she	ata ao ao		Art Unit	1623	
(Use as many sneeds as necessary)				Examiner Name	Not Yet Known	
Sheet	8	of 8	8	Attorney Docket Number	639-C-PCT-US	

Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/ESO/	74	Tsukagoshi, S., Y. Hashimoto, G. Fujii, H. Kobayashi, K. Nomoto, and K. Orita. 1984. "Krastin (PSK)", Cancer Treat. Rev. 11:131-155	
/ESO/	75	Vehricka, et al. 'Pilot Study: Orally-administered Yeast Beta 1,3-glucan Prophylactically protects against anthrex infection and cancer in mice'. Journ. Ameri. Nutraceutical Assoc., Vol. 5:2, April 22, 2002.	
/ESO/	76	Velvicka, V., B.P. Thornton and G.D. Ross, "Soluble 6-Glucan Polysaccharide Binding to the Lectin Site of Neutrophil or Natural Killer Cell Complement Receptor 1ype3 (CD1 tb/CD18) Generates a Primed State of the Receptor Capable of Mediating Cyclotoxicty of Ic3b-Openoized Target Cells". J. Clin. Invest., 98:504, 1,198.	
/ESO/	77	Xia, Y., V. Vetvicka, J. Yan, M. Hanikyrova, T. Mayadas and G.D. Ross, "The B-Glucan-Binding Lectin Site of Mouse CR3 (CD11b/CD18) and its Function in Generating a Primed State of the Receptor That Mediates Cytotocia Activation in Response to IC3b-Opsorioad Targed Cells", J. Immunology, 162:2281-2290, 1999.	
/ESO/	78	Yan, J. et al., "8-Glucan, a "Specific" Biologic Response Modifier That Uses Antibodies to Target Tumors for Cytotoic Recognition by Leukocyte Complement receptor Type 3 (CD11b/CD18). The Journal of Immunology, 183,3045-3052, 1999.	

Examiner	/Frie Olean/	Date	02/13/2008
Signature	/Eric Olson/	Considered	0111011000

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique cultation designation number (pollomat). Applicant is not place a check mark here if English lenguage Trenslation is ettached.

This conscious of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confiderability is governed by 33 U.S. C. 12 and 37 CFR 1.14. This collection is estimated to that 210 minutes to complete, including gathering, preparing, and submitting the completed episcation form to the USPTO. There will vary depending upon the individual case. Any comments on the amount of time you require to complete this form endors assigned that be applicable to sent to the CFR information Office. IV. 3 Department of Commence, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO. Commissioner for Patterns, Washington, DC 20231.